Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer

Administered By

Awarded By

Contributors

Start/End

  • August 12, 2016 - July 10, 2021